BeOne Medicines Ltd
688235
Company Profile
Business description
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.
Contact
c/o BeOne Medicines I GmbH
Aeschengraben 27
21st Floor
Basel4051
CHET: +41 616851900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
11,000
Stocks News & Analysis
stocks
Coinbase Earnings: Weak Cryptocurrency Prices Lead to Lower Trading Volume and Net Losses - Clone
We’ve lowered our fair value estimate of Coinbase stock.
stocks
Higher dividend for ASX member of our income pick list
Management lifted guidance and full-year dividend.
stocks
We expect sales growth to moderate for overvalued ASX share
Shares rallied after results but we see future headwinds.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,196.80 | 8.00 | -0.09% |
| CAC 40 | 8,316.50 | 4.76 | 0.06% |
| DAX 40 | 24,800.91 | 113.97 | -0.46% |
| Dow JONES (US) | 49,497.29 | 45.31 | 0.09% |
| FTSE 100 | 10,473.69 | 27.34 | 0.26% |
| HKSE | 26,705.94 | 138.82 | 0.52% |
| NASDAQ | 22,546.67 | 50.48 | -0.22% |
| Nikkei 225 | 56,786.73 | 19.68 | -0.03% |
| NZX 50 Index | 13,048.57 | 69.34 | -0.53% |
| S&P 500 | 6,840.79 | 8.03 | 0.12% |
| S&P/ASX 200 | 8,978.50 | 0.80 | -0.01% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |